Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?

被引：9

作者：

Bozza, Claudia ^{[1
]}

Fontanella, Caterina ^{[1
]}

Buoro, Vanessa ^{[1
]}

Mansutti, Mauro ^{[1
]}

Aprile, Giuseppe ^{[1
]}

机构：

[1] Univ Hosp Udine, Dept Med Oncol, I-33100 Udine, Italy

来源：

EXPERT REVIEW OF CLINICAL PHARMACOLOGY | 2015年 / 8卷 / 02期

关键词：

antiangiogenic drugs; breast cancer; monoclonal antibodies; tyrosine kinases inhibitors; VEGF; VEGFR; ENDOTHELIAL GROWTH-FACTOR; PHASE-III TRIAL; TYROSINE KINASE INHIBITOR; HER2-NEGATIVE LOCALLY RECURRENT; BEVACIZUMAB PLUS CAPECITABINE; ADVANCED SOLID TUMORS; 1ST-LINE TREATMENT; OPEN-LABEL; DOUBLE-BLIND; ANTITUMOR-ACTIVITY;

D O I：

10.1586/17512433.2015.1001837

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Since angiogenesis plays an important role in cancer growth, infiltration and metastasis, many agents targeting this pathway have been developed over the last decade. Antiangiogenic drugs interfere with this process and may inhibit neoplastic growth or induce tumor dormancy by blocking the expanding network of newly formed capillaries. Despite the initial promise, targeting angiogenesis in breast cancer has not reached major breakthroughs. Nevertheless, the immunologic role of VEGF deserves to be further explored. We aim to describe the biological mechanisms which underlie the role of angiogenesis in breast cancer carcinogenesis, to depict its contribution to the metastatic process and to review the most important clinical trials testing angiogenic inhibitors in breast cancer, including monoclonal antibodies and novel small molecules.

引用

页码：251 / 265

页数：15

共 94 条

[1]

Al-Halafi Ali M, 2014, Oman J Ophthalmol, V7, P112, DOI 10.4103/0974-620X.142591

[2] First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study [J].

Aogi, Kenjiro ;

Masuda, Norikazu ;

Ohno, Shinji ;

Oda, Takashi ;

Iwata, Hiroji ;

Kashiwaba, Masahiro ;

Fujiwara, Yasuhiro ;

Kamigaki, Shunji ;

Ito, Yoshinori ;

Ueno, Takayuki ;

Takashima, Shigemitsu .

BREAST CANCER RESEARCH AND TREATMENT, 2011, 129 (03) :829-838

[3] Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours [J].

Awada, Ahmad ;

Hendlisz, Alain ;

Christensen, Olaf ;

Lathia, Chetan D. ;

Bartholomeus, Sylvie ;

Lebrun, Fabienne ;

de Valeriola, Dominique ;

Brendel, Erich ;

Radtke, Martin ;

Delaunoit, Thierry ;

Piccart-Gebhart, Martine ;

Gil, Thierry .

EUROPEAN JOURNAL OF CANCER, 2012, 48 (04) :465-474

[4] Safety and Pharmacokinetics of Sorafenib Combined With Capecitabine in Patients With Advanced Solid Tumors: Results of a Phase 1 Trial [J].

Awada, Ahmad ;

Gil, Thierry ;

Whenham, Nicolas ;

Van Hamme, Julie ;

Besse-Hammer, Tatiana ;

Brendel, Erich ;

Delesen, Heinz ;

Joosten, Miranda C. ;

Lathia, Chetan D. ;

Loembe, Bienvenu A. ;

Piccart-Ghebart, Martine ;

Hendlisz, Alain .

JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (12) :1674-1684

[5] Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer [J].

Barrios, Carlos H. ;

Liu, Mei-Ching ;

Lee, Soo Chin ;

Vanlemmens, Laurence ;

Ferrero, Jean-Marc ;

Tabei, Toshio ;

Pivot, Xavier ;

Iwata, Hiroji ;

Aogi, Kenjiro ;

Lugo-Quintana, Roberto ;

Harbeck, Nadia ;

Brickman, Marla J. ;

Zhang, Ke ;

Kern, Kenneth A. ;

Martin, Miguel .

BREAST CANCER RESEARCH AND TREATMENT, 2010, 121 (01) :121-131

[6]

Baselga J, 2014, EUR SOC MED ONC 2014

[7] A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial [J].

Baselga, Jose ;

Costa, Frederico ;

Gomez, Henry ;

Hudis, Clifford A. ;

Rapoport, Bernardo ;

Roche, Henri ;

Schwartzberg, Lee S. ;

Petrenciuc, Oana ;

Shan, Minghua ;

Gradishar, William J. .

TRIALS, 2013, 14

[8] Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer [J].

Baselga, Jose ;

Martins Segalla, Jose Getulio ;

Roche, Henri ;

del Giglio, Auro ;

Pinczowski, Helio ;

Ciruelos, Eva M. ;

Cabral Filho, Sebastiao ;

Gomez, Patricia ;

Van Eyll, Brigitte ;

Bermejo, Begona ;

Llombart, Antonio ;

Garicochea, Bernardo ;

Climent Duran, Miguel Angel ;

Gehm Hoff, Paulo Marcelo ;

Espie, Marc ;

Junior Gemeinder de Moraes, Andre Augusto ;

Ribeiro, Ronaldo Albuquerque ;

Mathias, Clarissa ;

Gil Gil, Miguel ;

Ojeda, Belen ;

Morales, Josefa ;

Ro, Sunhee Kwon ;

Li, Shell ;

Costa, Frederico .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (13) :1484-1491

[9] Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer [J].

Bear, Harry D. ;

Tang, Gong ;

Rastogi, Priya ;

Geyer, Charles E., Jr. ;

Robidoux, Andre ;

Atkins, James N. ;

Baez-Diaz, Luis ;

Brufsky, Adam M. ;

Mehta, Rita S. ;

Fehrenbacher, Louis ;

Young, James A. ;

Senecal, Francis M. ;

Gaur, Rakesh ;

Margolese, Richard G. ;

Adams, Paul T. ;

Gross, Howard M. ;

Costantino, Joseph P. ;

Swain, Sandra M. ;

Mamounas, Eleftherios P. ;

Wolmark, Norman .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (04) :310-320

[10] Modes of resistance to anti-angiogenic therapy [J].

Bergers, Gabriele ;

Hanahan, Douglas .

NATURE REVIEWS CANCER, 2008, 8 (08) :592-603

← 1 2 3 4 5 6 7 8 9 10 →